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Cellular transplantation is rapidly becoming
recognized as a possible therapeutic approach in
human neurodegenerative disorders such as
Parkinson’s disease (PD). The transition from
basic research to broad scale clinical application
requires the clear demonstration of the safety of
this technology. A milestone in this transition
involves the identification of suitable cells for
transplantation. The use of dopaminergic tissue
derived from fetal or adrenal sources has been
explored in transplantation as a possible long-
term treatment for PD. In this approach, several
issues remain unresolved. First there has been
an inability to demonstrate long-term survival of
transplanted tissue with consistent functional
recovery in the clinical trials conducted to date.
Furthermore, the availability of donor tissue, the
amount of tissue needed to produce functional
recovery, the safety of the cell source, and the
ethical perception of using human fetal tissue
remain significant obstacles to the use of these
tissues.
The use of non-human donor cells provides
distinct advantages over human fetal cells as a
source of therapeutically transplanted cells. We
are developing a cellular transplant therapy for
PD based on the use of polymer encapsulation
to immuno-isolate animal cells. The cells we cur-
rently employ, PC12 cells, are an established tis-
sue culture line initially isolated from a rat
adrenomedullary chromaffin cell tumor. Trans-
plantation of encapsulated PC12 cells provides
specific safety advantages: the cells are rapidly
destroyed by the immune system if they escape
from immuno-isolation, the cells are free from
microbial and viral infections, and the cells are
grown under controlled conditions so that each
lot of cells will be from uniform, defined growth
stages. The key element to the successful appli-
cation of this technology lies in the immuno-
isolation of the cells. Cells are immuno-isolated
by surrounding them with a pe/’mselective poly-
mer membrane that allows nutrients to enter the
capsule so that the cells will survive and func-
tion. Additionally, the membrane is fabricated
such that the molecular weight cutoff allows
dopamine and other low molecular weight
molecules to leave the capsule.
Cellular encapsulation within polymeric hol-
low fibers can be achieved in several ways: cells
can be hand-loaded into pre-formed hollow
fibers or cells can be co-extruded with polymer
so that a continuous polymeric fiber forms
around the living cells. Both of these processes
require additional steps in which fibers are cut to
capsule size specifications and the ends of these
capsules are sealed. We have additionally devel-
oped a semi-automated, computer-controlled
version of the co-extrusion approach suitable for
rapidly manufacturing integrally sealed capsules.
This approach is rapid and its reproducibility
and safety is assured through hands-off process
validation.
Immuno-isolated capsules prepared from
polyacrylonitrile-vinyl chloride copolymer
(PAN/PVC) using sterile fabrication processes
are biocompatible following striatal implanta-
tion. Analysis of host tissue at the implant site
using light and electron microscopy has shown
that polymer capsules implanted into the rodent
or primate striatum produce a mild gliotic reac-
tion that rapidly diminishes over time. Inclusion
of PC12 cells within the capsule does not affect
the biocompatibility, suggesting that the encap-
sulated cells do not produce, or that the capsule
retains, physiologically active levels of inflamma-
tory or immune mediators.
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features not available in approaches using un-
encapsulated cells. Encapsulation enables the
use of qualified cell lines. Thus, cells can be used
which will grow under quarantine culture condi-
tions allowing sufficient time to meet FDA
guidelines for safety. Encapsulation enables
dosage control: cells can be either loaded to
prescribed densities (non-proliferating cell
types) or seeded to grow-up to fill a finite inter-
nal volume (proliferating cell types). Encapsula-
tion insures that transplanted cells are also
retrievable and can be rapidly and safely
removed in their entirety as therapeutically
required. Finally, appropriately selected cells
(i.e. animal cells) which escape encapsulation
will not survive unencapsulated.
The ultimate measure of the therapeutic util-
ity of encapsulated cells is in efficacy testing.
Encapsulated PC12 cells ameliorate apomor-
phine-induced rotation behavior and sensori-
motor deficits in 6-OHDA lesioned rats follow-
ing implantation into the denervated striatum.
The deficits in motor coordination and balance
which occur in aged rats are also partially re-
versed by the bilateral placement of encapsu-
lated PC12 cells into the striatum. Aebischer and
colleagues reported that encapsulated PC12
cells produced behavioral recovery in a
unilateral MPTP-treated primate. After intra-
striatal implantation of PC12 cells, the monkey’s
impaired performance in a motor dexterity
model improved significantly and the extent of
MPTP-induced tremor was reduced.
Pending the successful completion of addi-
tional preclinical efficacy and safety studies in
non-human primates we believe that the implan-
tation of encapsulated dopamine-secreting cells
into PD patients may provide an effective means
of alleviating the symptoms of the disease.
Furthermore, the technique of encapsulation
has applications in diseases other than PD that
are characterized by secretory cell dysfunction.